Merck posts earnings of 85 cents a share vs. 81 cents estimate

Analysts expected Merck to post earnings of 81 cents a share on revenue of $10.60 billion. In June, the company paid $3.85 billion for biotechnology company Idenix in an effort to build its presence in the hepatitis C drug sector.